Overview

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and autonomic dysfunction in obese normotensive subjects.
Phase:
N/A
Details
Lead Sponsor:
Emory University
Collaborator:
American Diabetes Association
Treatments:
Carvedilol
Salicylsalicylic acid
Sodium Salicylate
Soybean oil, phospholipid emulsion